Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05776069 · ClinicalTrials.gov registry record · Phase 1

Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)

A Phase 1 study of Von Willebrand Diseases, sponsored by Vega Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
116
Enrollment target
20
Study locations

NCT05776069 is a Phase 1 study of Von Willebrand Diseases that is actively recruiting participants, run by Vega Therapeutics. The registered enrollment target is 116 participants, below the 715-participant average among 5 other Von Willebrand Diseases trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05776069, a Phase 1 study of Von Willebrand Diseases, is actively recruiting participants, sponsored by Vega Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
116 participants
Enrollment target
20
Study locations

Study Summary

The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other bleeding disorders.

Conditions Studied

Von Willebrand Diseases

Interventions

  • OTHER Placebo
  • DRUG VGA039

Study Locations (20)

Ontario

  • Hamilton Health Sciences Corporation - Hamilton
  • Queens University - Kingston
  • St. Michaels Hospital - Toronto

California

  • Orthopedic Institute for Children (UCLA) - Los Angeles
  • UC Davis Medical Center - Sacramento

São Paulo

  • Hemocentro Unicamp - Campinas
  • Hospital das Clinicas - USP Endereco - São Paulo

Colorado

  • University of Colorado School of Medicine - Aurora

Georgia

  • Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory - Atlanta

North Carolina

  • Science 37, Inc. - Morrisville

Pennsylvania

  • Hemophilia Center of Western PA - Pittsburgh

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 116 participants
Start Date 2023-03-16
Est. Completion 2029-12
Phase Phase 1

Sponsor

Vega Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05776069

The ClinicalTrials.gov registry entry for NCT05776069 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 715-participant average among 5 other Von Willebrand Diseases trials with a reported enrollment target (84% lower). The listed sponsor is Vega Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Von Willebrand Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05776069 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Ontario, California, São Paulo.

Frequently Asked Questions

What is clinical trial NCT05776069 about?

NCT05776069 is a clinical study titled "Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)". The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other bleeding disorders.

What is the current status of trial NCT05776069?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2023-03-16. Estimated completion is 2029-12.

What conditions does trial NCT05776069 study?

This clinical trial studies the following conditions: Von Willebrand Diseases.

What interventions are being tested in trial NCT05776069?

The interventions under investigation include: Placebo (OTHER), VGA039 (DRUG).

Who is sponsoring clinical trial NCT05776069?

This trial is sponsored by Vega Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05776069 being conducted?

This trial has 20 study locations across California, Colorado, Georgia, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Von Willebrand Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Von Willebrand Diseases

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.